RINVOQ LQ Drug Patent Profile

When do Rinvoq Lq patents expire, and what generic alternatives are available?

Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twelve patent family members in forty-one countries.

The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rinvoq Lq

Rinvoq Lq was eligible for patent challenges on August 16, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (upadacitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for RINVOQ LQ

International Patents:	212
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	42
Patent Applications:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RINVOQ LQ
DailyMed Link:	RINVOQ LQ at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RINVOQ LQ

Constraining patent/regulatory exclusivity:

9,951,080

NDA:

218347

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RINVOQ LQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Berinstein, Jeffrey	PHASE4
AbbVie	PHASE4
AbbVie	PHASE3

See all RINVOQ LQ clinical trials

Pharmacology for RINVOQ LQ

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for RINVOQ LQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RINVOQ LQ	Oral Solution	upadacitinib	1 mg/mL	218347	1	2026-03-02

US Patents and Regulatory Information for RINVOQ LQ

RINVOQ LQ is protected by twelve US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,951,080.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	12,365,689
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	12,110,298			Y
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	9,951,080			Y
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	11,186,584			Y

EU/EMA Drug Approvals for RINVOQ LQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Rinvoq	upadacitinib	EMEA/H/C/004760Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.	Authorised	no	no	no	2019-12-16

International Patents for RINVOQ LQ

When does loss-of-exclusivity occur for RINVOQ LQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RINVOQ LQ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016340167
Australia	2020359635
Australia	2021236570
Australia	2023251492

Supplementary Protection Certificates for RINVOQ LQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506716	CA 2020 00011	Denmark		PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
2506716	301035	Netherlands		PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218
2506716	122020000011	Germany		PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216
2506716	LUC00149	Luxembourg		PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218

Rinvoq LQ (upadacitinib) market dynamics and financial trajectory: exclusivity, competitive threats, and revenue outlook

Last updated: June 7, 2026

Rinvoq LQ (upadacitinib) is a leading JAK inhibitor franchise within AbbVie’s immunology portfolio, with revenue driven by sustained prescription growth in rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and Crohn’s disease. Long-tail market risk concentrates on (1) patent and exclusivity cliffs for each approved indication, (2) competitive entry from other JAK inhibitors and TNF/IL-17/IL-23 biologics, and (3) switching risk driven by safety positioning, payer restrictions, and intolerance to JAK class effects.

---

What is Rinvoq LQ (upadacitinib) and where does it sell in immunology?

Fast answer: Rinvoq is the brand name for upadacitinib, an oral selective JAK1 inhibitor marketed for multiple immune-mediated diseases. Revenue exposure spans both established franchises (RA, PsA) and higher-growth extensions (AD, Crohn’s).

Indication-level demand drivers

Key demand drivers vary by immune-mediated disease and payer model:

• Rheumatoid arthritis (RA): steady conversions from csDMARD inadequacy and biologic-experienced populations; strong “time-to-response” profile supports formulary adoption.
• Psoriatic arthritis (PsA): uptake typically follows biologic switching patterns and line-of-therapy rules.
• Atopic dermatitis (AD): oral JAK inhibitor channel demand competes with dupilumab and JAK competitors where payer policy allows; dosing convenience supports persistence.
• Crohn’s disease: oral option can replace injectable therapies in payer-restricted pathways, but requires higher tolerance scrutiny and monitoring.

Drug form factor and “LQ” labeling impact

“LQ” is not a standard US label term for upadacitinib in FDA branding. If “LQ” refers to a specific long-term product line, label version, dosage strength, or non-US presentation, it changes substitution risk and market mapping. Without a concrete mapping of “LQ” to a specific strength, dosage form, or geography, financial trajectory must be treated at the franchise level.

---

How does Rinvoq’s market share evolve versus other JAK inhibitors and biologics?

Fast answer: Rinvoq’s share gains are tied to line-of-therapy expansion in multiple immunology indications and durable persistence, with market pressure mainly from class competition (oral JAKs) and mechanism-based biologics (IL-17/IL-23 in skin and IL-12/23/TNF in bowel and joint disease).

Competitive set by mechanism and geography

• JAK class competition: other oral JAK inhibitors compete on speed of symptom control and formulary status. Payer dynamics often decide whether a clinician can use them as preferred oral options.
• Biologics in AD and dermatology: biologics with strong efficacy-to-persistence profiles remain default options when payers prefer injection-based programs or when safety restrictions limit JAK use.
• Biologics in inflammatory bowel disease: competitive pressure from anti-TNF and gut-selective biologics increases with sequencing guidelines and prior authorization strictness.

What drives switching risk

Rinvoq switches are typically triggered by:

• loss of formulary position or step-therapy tightening
• adverse event management needs or discontinuation
• comparative payer contracting terms
• clinician preference after long-term data review
• emergence of updated safety communications affecting JAK use

---

What patent and exclusivity timeline risk exists for Rinvoq by indication?

Fast answer: For branded small molecules like upadacitinib, primary exclusivity risk is a function of (1) composition-of-matter patent expiration and (2) later-expiring method-of-use, formulation, and extension patents that can delay generic entry. Indication-by-indication regulatory milestones then shape when competitors can launch an “at-risk” generic or label carve-in.

How to read “expiration risk” for a multi-indication franchise

Rinvoq’s risk is not one date; it is a portfolio of:

• drug substance patents (composition of matter)
• formulation and manufacturing patents
• method-of-use patents (specific indications, patient subsets, or dosing regimens)
• regulatory exclusivities tied to first approvals or pediatric exclusivity where applicable

Practical impact on financial trajectory

• Approaching composition-of-matter expiration: increases probability of Paragraph IV filings or generic settlement focus.
• Approaching later patents (methods/formulations): can delay launch timing even after first patent sets expire.
• International divergence: non-US exclusivity and patent landscape can create earlier or parallel generic erosion abroad, affecting global net sales mix and bargaining power.

---

What is the Orange Book status of Rinvoq LQ, and how many listed patents matter?

Fast answer: Orange Book coverage must be mapped to the specific marketed strength and dosage form tied to “LQ.” Patent counts and expiration dates vary by strength and by listed supplement records.

Why Orange Book mapping changes the analysis

For multi-strength brands, each NDC maps to a subset of patents with distinct expiration dates. The number of active patents and the latest expiring entry date can materially change:

• the latest at-risk generic launch window
• settlement leverage for AbbVie
• litigation breadth if a challenger targets only one NDC or only one indication label

No Orange Book patent dataset was provided here. Without a defined NDC/strength for “LQ,” an accurate patent-count and expiration timeline cannot be stated in a way that supports litigation, licensing, or investment use.

---

How often do Paragraph IV challenges occur for Rinvoq, and what does that imply for generic entry risk?

Fast answer: Paragraph IV challenge risk rises as composition-of-matter and key extension patents near expiration, and as challengers see settlement upside based on expected launch timelines and label coverage.

What a Paragraph IV pattern means commercially

• High filing velocity near expiration window: indicates multiple challengers expect a favorable “carve-out” position or settlement.
• Narrow targeting of specific strengths/NDCs: indicates challengers plan segmented launch strategies to minimize litigation and maximize speed.
• Repeated stays and settlements: reduces near-term at-risk entry probability but can shift launch timing in later years.

No litigation docket or FDA Paragraph IV listing data was provided here, so a verified “how many challenges” statement would be speculative.

---

What patent litigation affects Rinvoq, and what is the settlement/launch scenario?

Fast answer: For high-revenue small molecules, litigation typically covers composition, method-of-use, and formulation claims. Outcomes shape launch timing for generics and can create staggered entry across strengths and indications.

What to model for financial trajectory

A credible revenue forecast usually models:

• probability of generic entry by each NDC strength
• timing of settlement-based “authorized generic” or “launch carve-out”
• erosion ramp rate driven by payer substitution rules and ongoing prescriber switching
• brand defensibility from contracting and patient support programs

No certified complaint or settlement documentation for “Rinvoq LQ” was provided here, so no verified litigation event list can be produced.

---

How strong is the patent estate for upadacitinib versus competing JAK inhibitors?

Fast answer: The strength assessment for upadacitinib depends on whether its later-expiring patents cover:

• dosing regimens
• patient selection criteria
• specific indication method-of-use claims
• formulations that improve bioavailability, tolerability, or dosing adherence

Competitive comparison framework

• If competitors launch generics soon after composition expiration: AbbVie’s later patents must withstand “generic equivalence” arguments tied to bioavailability and labeling instructions.
• If later patents protect key clinical methods: challengers may face “skinny label” or delayed entry.
• If method-of-use protection is weaker: quicker erosion risk increases even if formulation patents expire later.

A quantified strength comparison requires an identified patent list and expiration dates, which are not included in the prompt.

---

What is the FDA regulatory status and exclusivity landscape for Rinvoq across indications?

Fast answer: Rinvoq has a multi-indication FDA approval footprint with ongoing label expansions across immunology. Regulatory status affects commercial uptake and can also influence the attractiveness of generic or biosimilar substitution in practice.

Pathway and label expansion impact

• Broader label expansions increase the addressable market.
• New safety communications or REMS-like monitoring expectations can slow conversion or increase churn if payers restrict access.
• Real-world utilization may diverge from label breadth due to payer step therapy.

No FDA status detail set was supplied for “Rinvoq LQ”, so no verified, indication-specific regulatory milestone timeline can be stated.

---

How does Rinvoq’s financial trajectory map to dosing penetration, persistence, and payer controls?

Fast answer: Franchise financial performance is driven by patient counts, average net price (net of rebates/discounts), and persistence. For JAK inhibitors, payer restrictions and safety-driven access limits can alter both volume and net price.

Revenue architecture to track (what moves the P&L)

• New starts: influenced by guideline positioning, formulary inclusion, and prior authorization processing speed.
• Persistence/continuation: influenced by adverse-event tolerability and switching to alternative mechanisms.
• Line-of-therapy mix: biologic-experienced patients often pay at lower net prices due to contracting.
• Geographic mix: US typically leads profitability; ex-US dynamics affect growth and margin stability.

Scenario model for forward trajectory

Use three revenue drivers and one erosion trigger:

1. Volume trend: new patient starts into RA/PsA and growth in AD/Crohn’s.
2. Net price: rebate pressure from contracting; JAK competition can depress net price.
3. Mix shift: higher growth indications can lift growth but may come with tighter payer controls.
4. Erosion trigger: any generic “at-risk” or authorized entry event by NDC/strength.

Without a specified time range and confirmed patent/litigation milestones for “LQ,” only the framework can be stated.

---

What generic entry risks exist for Rinvoq LQ, and what would happen to net sales?

Fast answer: Generic risk is concentrated around the expiration of the last binding patents for the exact NDC(s) supporting “LQ.” If entry occurs, net sales erosion typically follows a ramp tied to payer substitution and ongoing brand support.

Likely erosion mechanics

• Immediate payer switch when “preferred generic” status is granted
• Formulary reinstatement of brand through contracting may slow erosion but usually not prevent it
• Segmented entry by strength can create uneven erosion
• Skinny label realities can preserve some use cases but rarely prevent overall category decline

A quantified erosion forecast requires launch dates and Orange Book NDC-specific patent expirations, which are not provided.

---

Key Takeaways

• Rinvoq’s market dynamics reflect a multi-indication JAK inhibitor franchise where revenue growth depends on patient starts and persistence across RA, PsA, AD, and Crohn’s.
• Competitive pressure is primarily driven by payer preference, safety perceptions, and substitution threats from other oral JAK inhibitors and mechanism-based biologics.
• The central financial risk is not one date. It is the NDC-specific patent and exclusivity schedule tied to the exact “Rinvoq LQ” product configuration, plus Paragraph IV and litigation outcomes.
• Generic entry impact would likely show as payer-driven category substitution with net price pressure and patient churn, unless brand contracting offsets substitution speed.

---

FAQs

1. What shortens Rinvoq’s time-to-generic erosion even before full patent expiration?
2. Which Rinvoq indications typically face the fastest payer-driven substitution risk?
3. How do adverse-event or safety communications for JAK inhibitors affect formulary access?
4. What matters more for revenue protection: method-of-use patents or composition-of-matter patents?
5. How should analysts model net sales after a segmented generic launch by strength?

---

References (APA)

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. AbbVie. Annual reports and quarterly earnings releases for upadacitinib (Rinvoq) net revenue disclosures.
3. FDA Drug Trials Snapshots and labeling for Rinvoq (upadacitinib). U.S. Food and Drug Administration.